Early stage pharma forecasting can be a valuable exercise helping to drive clinical development and commercialization efforts, or end up as a “check the box” activity given merely an afterthought in strategic planning efforts. The difference is all in the approach. Early forecast numbers may be of little strategic value when projections are made without factoring market environmental trends and consumer behavioral tendencies.